AR107193A2 - Compuesto de benzoazepina hidrosoluble y composición farmacéutica - Google Patents

Compuesto de benzoazepina hidrosoluble y composición farmacéutica

Info

Publication number
AR107193A2
AR107193A2 ARP160104016A ARP160104016A AR107193A2 AR 107193 A2 AR107193 A2 AR 107193A2 AR P160104016 A ARP160104016 A AR P160104016A AR P160104016 A ARP160104016 A AR P160104016A AR 107193 A2 AR107193 A2 AR 107193A2
Authority
AR
Argentina
Prior art keywords
benzoazepine compound
hydrosoluble
pharmaceutical composition
optionally protected
group optionally
Prior art date
Application number
ARP160104016A
Other languages
English (en)
Inventor
Kato Yusuke
Matsuda Takakuni
Yamada Keigo
Menjo Yasuhiro
Goto Fumitaka
Komatsu Makoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37877008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR107193(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR107193A2 publication Critical patent/AR107193A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El compuesto de benzoazepina de la presente y sus sales tienen una alta hidrosolubilidad y se pueden utilizar convenientemente para inyecciones. Reivindicación 1: Un compuesto de benzoazepina representado por la fórmula general (1), o su sal, en la cual R representa un átomo de hidrógeno, un grupo hidroxi opcionalmente protegido por un grupo protector, un grupo mercapto opcionalmente protegido por un grupo protector, o un grupo amino opcionalmente protegido por uno o dos grupos protectores; R¹ representa un átomo de hidrógeno o un grupo hidroxi-protector; y X representa un átomo de oxígeno o un átomo de azufre.
ARP160104016A 2005-12-27 2016-12-26 Compuesto de benzoazepina hidrosoluble y composición farmacéutica AR107193A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005375457 2005-12-27

Publications (1)

Publication Number Publication Date
AR107193A2 true AR107193A2 (es) 2018-03-28

Family

ID=37877008

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060105779A AR058737A1 (es) 2005-12-27 2006-12-26 Compuestos de benzoazepina con actividad hipotensora hidrosoluble y composicion farmaceutica inyectable que los comprende.
ARP160104016A AR107193A2 (es) 2005-12-27 2016-12-26 Compuesto de benzoazepina hidrosoluble y composición farmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060105779A AR058737A1 (es) 2005-12-27 2006-12-26 Compuestos de benzoazepina con actividad hipotensora hidrosoluble y composicion farmaceutica inyectable que los comprende.

Country Status (23)

Country Link
US (6) US20100004206A1 (es)
EP (2) EP1968990B1 (es)
JP (2) JP4644287B2 (es)
KR (1) KR101008931B1 (es)
CN (1) CN101346390B (es)
AR (2) AR058737A1 (es)
AU (1) AU2006330277B2 (es)
BR (1) BRPI0620715A2 (es)
CA (1) CA2633929A1 (es)
CY (1) CY1116208T1 (es)
DK (1) DK1968990T3 (es)
ES (1) ES2533007T3 (es)
HK (1) HK1121461A1 (es)
IL (1) IL191935A (es)
MY (1) MY146042A (es)
NO (1) NO342436B1 (es)
PL (1) PL1968990T3 (es)
PT (1) PT1968990E (es)
RU (1) RU2418804C2 (es)
SI (1) SI1968990T1 (es)
TW (1) TWI323257B (es)
WO (1) WO2007074915A1 (es)
ZA (1) ZA200805011B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5590780B2 (ja) * 2007-06-26 2014-09-17 大塚製薬株式会社 医薬
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
WO2009149493A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
CN102020609A (zh) * 2009-09-17 2011-04-20 北京本草天源药物研究院 托伐普坦晶体或无定形物及其制备方法
DE102010041263A1 (de) * 2010-09-23 2012-03-29 Siemens Medical Instruments Pte. Ltd. Hörgerätegehäuse mit Dichtungslippe
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
MX2015008220A (es) * 2012-12-28 2015-09-29 Otsuka Pharma Co Ltd Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un proceso para producir la misma.
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
JP7016853B2 (ja) * 2016-07-07 2022-02-07 サイクレリオン・セラピューティクス，インコーポレーテッド ｓＧＣ刺激剤のリンプロドラッグ
JP2021014406A (ja) * 2017-10-25 2021-02-12 トーアエイヨー株式会社 バソプレシン受容体拮抗剤
KR20210121128A (ko) 2019-01-30 2021-10-07 오츠카 세이야쿠 가부시키가이샤 벤조아제핀 화합물의 제조 방법
WO2020196814A1 (en) 2019-03-28 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Benzoazepine compound-containing freeze-dried composition
JP7130879B2 (ja) * 2019-03-28 2022-09-05 大塚製薬株式会社 ベンゾアゼピン化合物含有医薬組成物
JP2024506365A (ja) 2021-02-10 2024-02-13 上海森▲輝▼医▲葯▼有限公司 ベンゾアゼピン系化合物及びその調製方法並びに医薬用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
TW198715B (es) 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
US5972882A (en) * 1997-12-15 1999-10-26 University Of Kansas Medical Center Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
CY1116208T1 (el) 2017-02-08
US9303052B2 (en) 2016-04-05
ES2533007T3 (es) 2015-04-06
US20120277188A1 (en) 2012-11-01
TW200734309A (en) 2007-09-16
JP2011046731A (ja) 2011-03-10
US20100004206A1 (en) 2010-01-07
US9809609B2 (en) 2017-11-07
CN101346390A (zh) 2009-01-14
AR058737A1 (es) 2008-02-20
PL1968990T3 (pl) 2015-06-30
EP1968990B1 (en) 2015-02-11
JP5550522B2 (ja) 2014-07-16
US20110082110A1 (en) 2011-04-07
DK1968990T3 (da) 2015-04-27
IL191935A0 (en) 2008-12-29
IL191935A (en) 2013-07-31
NO20082630L (no) 2008-09-16
SI1968990T1 (sl) 2015-05-29
AU2006330277A1 (en) 2007-07-05
TWI323257B (en) 2010-04-11
CN101346390B (zh) 2011-11-09
EP2674436A1 (en) 2013-12-18
US20110098250A1 (en) 2011-04-28
BRPI0620715A2 (pt) 2011-11-22
PT1968990E (pt) 2015-03-16
CA2633929A1 (en) 2007-07-05
KR101008931B1 (ko) 2011-01-17
JP4644287B2 (ja) 2011-03-02
WO2007074915A8 (en) 2007-11-08
EP1968990A1 (en) 2008-09-17
WO2007074915A1 (en) 2007-07-05
US20130331358A1 (en) 2013-12-12
KR20080078916A (ko) 2008-08-28
US20120277189A1 (en) 2012-11-01
RU2418804C2 (ru) 2011-05-20
NO342436B1 (no) 2018-05-22
ZA200805011B (en) 2009-11-25
HK1121461A1 (en) 2009-04-24
RU2008130887A (ru) 2010-02-10
MY146042A (en) 2012-06-15
JP2009521397A (ja) 2009-06-04
AU2006330277B2 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
AR107193A2 (es) Compuesto de benzoazepina hidrosoluble y composición farmacéutica
AR057035A1 (es) SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
AR064842A1 (es) Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep
AR053547A1 (es) Composiciones de sales anti transpirantes de aluminio o aluminio- zirconio de eficacia acrecentada que contienen sal (es) de calcio y betaina
AR065845A1 (es) Quinolonas y tetrahidroquinolinas y compuestos relacionados con actividad inhibidoria de nos
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
EA200901329A1 (ru) Применение пиридин-2-окси-3-карбонамидов в качестве защитных средств
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ES2421613T3 (es) Composición farmacéutica externa
AR061134A1 (es) Derivados de tioxantina
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
UY28006A1 (es) Agonistas ppar quirales
NO20091101L (no) Farmasoytisk formulering inneholdenede fenylamidin derivativ og anvendelsesmetode for farmasoytisk formulering i combinasjon med en antifungal agent
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
AR065724A1 (es) Macrolidos
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
HUP0100564A2 (hu) Matrix metalloproteináz inhibitorok és ilyeneket tartalmazó gyógyszerkészítmények
UY29714A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure